Testified at a hearing before the U.S. House of Representatives' Committee on Ways and Means as a neutral ERISA pundit regarding Appropriateness of 401(k) Fees
This event has already occurred.
Related Insights
Longer Holds, Hidden Value: Five IP Questions Private Equity Sponsors Should Ask
October 26 - 28, 2026Chicago, IL
- University of Chicago Law School
Skinny Labels and Beyond: How the Same Pharmaceutical Patent Can Yield Different Outcomes — And What Recent International High Court Rulings Mean for Your Global Strategy